期刊文献+

二肽基肽酶-4抑制剂影响胰岛β细胞机制的研究进展 被引量:4

Research progress of mechanism of the effect of DPP-4 inhibitors on pancreatic beta cells
原文传递
导出
摘要 二肽基肽酶-4(DPP-4)抑制剂减轻内质网负担和线粒体氧化应激,进而促进胰岛β细胞增殖分化;上调抗氧化应激相关的基因,如Cat、Gpxt及Sod2等,抑制硝基酪氨酸生成;下调脂质合成的基因表达,降低血载脂蛋白B、LDL-C、TG、TC和FFA水平;下调一氧化氮(NO)和TNF-α等炎症因子的浓度;刺激胰岛β细胞分泌胰淀素,但不会促进其的沉积,且对胰淀素所引起的胰岛β细胞的丧失有保护作用;从而改善了胰岛β细胞功能,增加了其质量,延缓了其衰竭。 DPP-4 inhibitors can alleviate the endoplasmic reticulum stress and mitochondrial oxidative stress to promote the proliferation and differentiation of beta-cells; up-regulate anti-oxidative stress genes,such as Cat,Gpxt and Sod2,and inhibit the production of nitrotyrosine; down-regulate the expression of lipid synthesis genes,and reduce levels of apolipoprotein B,low density lipoprotein,triglycerides,total cholesterol,and free fatty acids; reduce concentrations of inflammatory cytokines like NO and TNF-α; stimulate pancreatic beta-cells to secrete amylin without promoting its deposition,and have protective function for the loss of pancreatic beta cells caused by amylin; therefore improve the function of pancreatic beta cells,increase their mass,and delay their failure.
作者 董莹 李强
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2014年第10期953-955,共3页 Chinese Journal of Diabetes
基金 国家自然科学基金(81170744 81370902) 中华医学会临床医学科研专项(13020180403)
关键词 二肽基肽酶-4抑制剂 胰岛Β细胞 内质网应激 氧化应激 脂毒性 Dipeptidyl peptidase-4 (DPP-4) inhibitor Pancreatic beta-cell Endoplasmic reticulum stress Oxidative stress Lipotoxicity
  • 相关文献

参考文献1

二级参考文献39

  • 1Perley M J, Kipnis DM. Plasma insulin responses to oral andintravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954-62.
  • 2Bonora E. Protection of pancreatic beta-cells: is it feasible? Nutr Metab Cardiovasc Dis 2008; 18: 74-83.
  • 3Del Prato S, Penno G, Miccoli R. Changing the treatment paradigm for type 2 diabetes. Diabetes Care 2009; 32: 217-22.
  • 4Cefalu WT, Richards R J, Melendez-Ramircz LY. Redefining treatment success in type 2 diabetes mellitus: comprehensive targeting of core defects. Cleve Clin J Med 2009; 76: 39-47.
  • 5Nauck MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009; 32: 223-31.
  • 6Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther 2010; 125: 328-61.
  • 7Hoist JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-l. Diabetes Metab Res Rev 2002; 18: 430-41,.
  • 8Ahren B, Larsson H, Hoist JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 473-8.
  • 9Willms B, Werner J, Hoist JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP- 1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996: 81: 327-32.
  • 10Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Hoist J J, et al, Energy intake and appetite are suppressed by glucagon-like peptide-i (GLP-1) in obese men. Int J Obes ReLat Metab Disord 1999; 23: 304- 11.

共引文献3

同被引文献37

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部